Assessing Whether Axon Enterprise (AXON) Still Justifies Its High Valuation After Recent Pullback

Axovant Sciences Ltd -2.54%

Axovant Sciences Ltd

AXON

412.81

-2.54%

  • If you are wondering whether Axon Enterprise at around US$549.86 still makes sense for your portfolio, the key question is how its current share price compares with a fair value estimate.
  • The stock has seen a 9.9% decline over the last 7 days, a 5.3% decline over the last 30 days, a 2.4% decline year to date, but a very large gain over 5 years, so recent weakness sits against a strong longer term return profile.
  • Recent coverage of Axon Enterprise has focused on its role as a provider of public safety technology and how that positions the business within law enforcement and public sector budgets. This context helps frame why the stock can experience sharp short term moves even when the long term story attracts investor attention.
  • Right now, Axon Enterprise scores a 1 out of 6 valuation check score, which signals only one area where the stock looks undervalued. In the sections that follow, we will look at how different valuation methods assess the shares and then finish with a broader way to think about value that goes beyond just the numbers.

Axon Enterprise scores just 1/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Axon Enterprise Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model estimates what a company might be worth by projecting its future cash flows and then discounting those amounts back to today so everything is expressed in present day US$ terms.

For Axon Enterprise, the model uses a 2 stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is about $148 million. Analyst forecasts and extrapolated estimates from Simply Wall St project free cash flow reaching $1,129.454 million in 2028, with further projections out to 2035 included in the calculation.

Bringing all those projected cash flows back to today gives an estimated intrinsic value of about $455.51 per share. Compared with the recent share price of around $549.86, the DCF output suggests the stock is around 20.7% overvalued on this set of assumptions.

This is a model driven result, but on these numbers, Axon Enterprise screens as expensive rather than cheap.

Result: OVERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Axon Enterprise may be overvalued by 20.7%. Discover 880 undervalued stocks or create your own screener to find better value opportunities.

AXON Discounted Cash Flow as at Jan 2026
AXON Discounted Cash Flow as at Jan 2026

Approach 2: Axon Enterprise Price vs Sales

For a company like Axon Enterprise, where investors often focus on revenue traction alongside profitability, the P/S ratio can be a useful way to think about what the market is paying for each dollar of sales.

In general, higher growth expectations and lower perceived risk can support a higher “normal” P/S multiple, while slower expected growth or higher risk tends to line up with a lower multiple. That context helps when you compare one company with its sector or with similar businesses.

Axon Enterprise is currently trading on a P/S of 17.08x. This sits above the Aerospace & Defense industry average P/S of 3.76x and above the peer group average of 8.26x. Simply Wall St’s Fair Ratio for Axon Enterprise is 14.67x, which is their view of what a reasonable P/S might be given factors like the company’s earnings growth profile, industry, profit margins, market cap and risk characteristics.

The Fair Ratio is more tailored than a simple peer or industry comparison because it adjusts for company specific features rather than assuming one size fits all. Setting the current 17.08x P/S against the 14.67x Fair Ratio suggests the shares are pricing in more optimism than that model supports.

Result: OVERVALUED

NasdaqGS:AXON P/S Ratio as at Jan 2026
NasdaqGS:AXON P/S Ratio as at Jan 2026

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1419 companies where insiders are betting big on explosive growth.

Upgrade Your Decision Making: Choose your Axon Enterprise Narrative

Earlier we mentioned that there is an even better way to think about value, and that is through Narratives, which let you attach a clear story to your numbers by linking your view of Axon Enterprise’s future revenue, earnings and margins to a financial forecast and then to your own fair value estimate.

On Simply Wall St’s Community page, used by millions of investors, you can build or follow Narratives that show a fair value and compare it directly with today’s share price so you can judge for yourself whether Axon Enterprise looks attractive, fully priced, or stretched based on your assumptions.

Narratives are kept current as new information comes in. When there is fresh news or an earnings report, the forecast and fair value update, which helps you quickly reassess whether the gap between price and value still supports holding, trimming or adding.

For example, one Axon Enterprise Narrative might assume very strong revenue growth and higher long term margins that justify a fair value well above the current price. Another might assume more moderate growth and lower margins that lead to a fair value well below where the stock trades today.

Do you think there's more to the story for Axon Enterprise? Head over to our Community to see what others are saying!

NasdaqGS:AXON 1-Year Stock Price Chart
NasdaqGS:AXON 1-Year Stock Price Chart

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.